The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling

Department of Pathology and Immunology, Washington University School of Medicine, Campus Box 8118, 660 South Euclid Avenue, St. Louis, Missouri 63110, USA.
Journal of Clinical Investigation (Impact Factor: 13.77). 08/2004; 114(2):206-13. DOI: 10.1172/JCI15797
Source: PubMed

ABSTRACT Highly active antiretroviral therapy (HAART), which includes HIV protease inhibitors (PIs), has been associated with bone demineralization. To determine if this complication reflects accelerated resorptive activity, we studied the impact of two common HIV PIs, ritonavir and indinavir, on osteoclast formation and function. Surprisingly, we find that ritonavir, but not indinavir, inhibits osteoclast differentiation in a reversible manner and also abrogates bone resorption by disrupting the osteoclast cytoskeleton, without affecting cell number. Ritonavir given in vivo completely blunts parathyroid hormone-induced osteoclastogenesis in mice, which confirms that the drug is bone sparing. In keeping with its antiresorptive properties, ritonavir impairs receptor activator of nuclear factor kappaB ligand-induced (RANKL-induced) activation of NF-kappaB and Akt signaling pathways, both critical to osteoclast formation and function. In particular, ritonavir is found to inhibit RANKL-induced Akt signaling by disrupting the recruitment of TNF receptor-associated factor 6/c-Src complex to lipid rafts. Thus, ritonavir may represent a bone-sparing PI capable of preventing development of osteopenia in patients currently on HAART.

Download full-text


Available from: Steven Teitelbaum, Sep 22, 2014
  • Source
    • "Adherent cells were cultured for 7 days in α-MEM supplemented with 20% FCS to stimulate proliferation of BMSCs. Thereafter, stromal cells and macrophages were released from their respective dishes, mixed (3.4x10 5 each), and seeded in a 24-well plate in α-MEM supplemented with 10% FBS, 10nM vitamin D3 and 100nM dexamethasone (Wang et al., 2004). These cocultures were incubated for 7 days, and then stained for TRAP as described above. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Connexin43 (Cx43) has an important role in skeletal homeostasis, and Cx43 gene (Gja1) mutations have been linked to oculodentodigital dysplasia (ODDD), a human disorder characterized by prominent skeletal abnormalities. To determine the function of Cx43 at early steps of osteogenesis and its role in the ODDD skeletal phenotype, we have used the Dermo1 promoter to drive Gja1 ablation or induce an ODDD mutation in the chondro-osteogenic linage. Both Gja1 null and ODDD mutant mice develop age-related osteopenia, primarily due to a progressive enlargement of the medullary cavity and cortical thinning. This phenotype is the consequence of a high bone turnover state, with increased endocortical osteoclast-mediated bone resorption and increased periosteal bone apposition. Increased bone resorption is a noncell autonomous defect, caused by exuberant stimulation of osteoclastogenesis by Cx43-deficient bone marrow stromal cells, via decreased Opg production. The latter is part of a broad defect in osteoblast differentiation and function, which also results in abnormal structural and material properties of bone leading to decreased resistance to mechanical load. Thus Cx43 in osteogenic cells is a critical regulator of both arms of the bone remodeling cycle, its absence causing structural changes remindful of aged or disused bone.
    Molecular biology of the cell 02/2011; 22(8):1240-51. DOI:10.1091/mbc.E10-07-0571 · 5.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In HIV-infected persons, osteoporosis is common and has a multifactorial etiology including traditional risk factors, such as smoking and low body weight, as well as direct effects of HIV infection and antiretroviral therapy. Multiple studies indicate that HIV-infected persons are at increased risk of low bone mass as compared to the general population. Emerging data suggest that the increased prevalence of reduced bone mass in HIV infection predisposes patients to an increased risk of fracture. This review discusses the epidemiology of low bone mass and fracture in HIV-infected persons, addresses the multiple causes of reduced bone mineral density in HIV infection, and offers recommendations on screening HIV-infected persons for bone loss.
    Clinical Reviews in Bone and Mineral Metabolism 12/2012; 10(4). DOI:10.1007/s12018-012-9132-z
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Osteoporosis commonly affects older men and women. Frequently, it is caused or exacerbated by a disease or treatment (termed secondary osteoporosis). The aim of this thesis is to explore aspects of the pathogenesis and treatment of three conditions that may cause or contribute to osteoporosis: human immunodeficiency virus (HIV) infection, primary hyperparathyroidism (PHPT), and vitamin D insufficiency. Each of these conditions is potentially linked to bone metabolism via associations with nutritional status, which in turn is a key regulator of bone mass and fracture risk. Methods: Eight studies were performed: 1. Cross-sectional comparison of bone mineral density (BMD) in HIV-infected men and age-matched controls. 2. Two-year randomised controlled trial of the effects of annual zoledronate on BMD in HIV-infected men. 3. Longitudinal comparison of the change in BMD over two years in HIV-infected men not receiving skeletal therapy and controls. 4. Meta-analysis of body weight in patients with PHPT. 5. Cross-sectional analysis of the relationship between parathyroid hormone and body weight in post-menopausal women. 6. Cross-sectional analysis of the determinants of 25-hydroxyvitamin D (25OHD) in post-menopausal women and middle-aged and older men. 7. Cross-sectional analysis of the effects of fat mass and seasonal variation on diagnosis of vitamin D sufficiency. 8. Cross-sectional analysis of the relationship between vitamin D binding protein and body weight in older men and women. Results: 1. HIV-infected men were 6.3 kg lighter than controls, and after adjustment for this weight difference, did not have lower BMD than controls. 2. Annual intravenous zoledronate caused substantial increases in BMD in HIV-infected men over two years. 3. HIV-infected men did not have accelerated bone loss over time compared to controls. 4. Patients with PHPT are on average 3.1-3.3 kg heavier than age-matched controls. 5. Fat mass is an important determinant of parathyroid hormone levels. 6. The major determinants of 25OHD levels in men and women are surrogate measures of ultraviolet-B exposure, and fat mass, but men have higher 25OHD levels throughout the year than women. 7. Thresholds for diagnosis of vitamin D sufficiency vary by season and amount of fat mass. 8. Vitamin D binding protein does not mediate the relationships between 25OHD and age, gender or weight. Conclusions: Uncomplicated HIV infection is not associated with low BMD at baseline or accelerated bone loss over time. There are important relationships between body weight and PHPT, and among fat mass, parathyroid hormone and 25OHD that have significance both for the pathogenesis of PHPT and vitamin D sufficiency, and for the clinical diagnosis and treatment of these conditions.
Show more